Recruiting

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

I8S-MC-JUAB - ClinicalTrials.gov - NCT02857270

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Email
Recruiting

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

I8S-MC-JUAB - ClinicalTrials.gov - NCT02857270

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have advanced, unresectable or metastatic cancer (solid tumors)

Participants must NOT

Participant must not have known HIV infection or hepatitis A, B, or C

Participant must not have current blood cancers, acute or chronic leukemia

Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor - Female participant must not be pregnant, breastfeeding, or planning to become pregnant

Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy. Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor.

Trial Summary

Conditions the trial is for

Advanced Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer

What the trial is testing?

LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Cetuximab, Encorafenib

Could I receive a Placebo?

no

Enrollment Goal

245

Trial Dates

September 2016 - September 2021

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have advanced, unresectable or metastatic cancer (solid tumors)

Participants must NOT

Participant must not have known HIV infection or hepatitis A, B, or C

Participant must not have current blood cancers, acute or chronic leukemia

Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor - Female participant must not be pregnant, breastfeeding, or planning to become pregnant

Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy. Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor.

Trial Summary

Conditions the trial is for

Advanced Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer

What the trial is testing?

LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Cetuximab, Encorafenib

Could I receive a Placebo?

no

Enrollment Goal

245

Trial Dates

September 2016 - September 2021

Trial Phase

1

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?